Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G
Department of Internal Medicine and Medical Therapeutics, University of Pavia, Italy.
Kidney Int. 1994 Sep;46(3):869-76. doi: 10.1038/ki.1994.344.
Target-specific oxidation processes in LDL generate molecular epitopes that are more atherogenic than the native forms and are able to elicit an immunological reaction leading to the formation of anti-oxLDL autoantibodies (oxLDL-Ab) that may participate in the overall process of atherogenesis. Thus, the detection of oxLDLAb, in addition to mirroring the occurrence of in vivo LDL oxidation, will give valuable information on the occurrence of this immune response. Plasma oxLDLAb (IgG and IgM) were measured in 72 control subjects (CS) and in 80 patients with chronic renal failure (CRF), undergoing repetitive hemodialysis (N = 56) or peritoneal dialysis (N = 24), with an ELISA method using native LDL, CuSO4-oxidized LDL (oxLDL) or malondialdehyde-derivatized LDL (MDA-LDL) as antigens. To monitor cross reactivity of the antibodies detected with other oxidatively-modified proteins, human serum albumin (HSA) and MDA-derivatized HSA (MDA-HSA) were also employed as antigens. The antibody titer was calculated as the ratio of antibodies against modified versus native proteins. CRF patients had an antibody ratio significantly higher than CS as concerning anti-oxLDL IgG (1.39 +/- 0.36 vs. 1.05 +/- 0.3, P < 0.05) and IgM (2.15 +/- 0.75 vs. 1.43 +/- 0.43, P < 0.01), and anti-MDA-LDL IgG (3.05 +/- 0.74 vs. 2.04 +/- 0.42, P < 0.01) and IgM (5.55 +/- 1.79 vs. 2.9 +/- 0.85, P < 0.01). The anti-MDA-HSA antibody titer was also higher in CRF patients than in CS (2.49 +/- 0.5 vs. 1.46 +/- 0.39, P < 0.01 for IgG and 2.80 +/- 1.03 vs. 1.26 +/- 0.43, P < 0.01 for IgM).(ABSTRACT TRUNCATED AT 250 WORDS)
低密度脂蛋白（LDL）中针对特定靶点的氧化过程会产生分子表位，这些表位比天然形式的更具致动脉粥样硬化性，并且能够引发免疫反应，导致抗氧化型LDL自身抗体（oxLDL-Ab）的形成，而这种抗体可能参与动脉粥样硬化的整个过程。因此，检测oxLDL-Ab，除了能反映体内LDL氧化的发生情况外，还将提供有关这种免疫反应发生情况的有价值信息。采用酶联免疫吸附测定（ELISA）方法，以天然LDL、硫酸铜氧化的LDL（oxLDL）或丙二醛衍生的LDL（MDA-LDL）作为抗原，检测了72名对照受试者（CS）以及80名慢性肾衰竭（CRF）患者血浆中的oxLDL-Ab（IgG和IgM），这些CRF患者接受重复血液透析（N = 56）或腹膜透析（N = 24）。为监测所检测抗体与其他氧化修饰蛋白的交叉反应性，还采用人血清白蛋白（HSA）和丙二醛衍生的HSA（MDA-HSA）作为抗原。抗体滴度计算为针对修饰蛋白与天然蛋白的抗体比值。CRF患者的抗体比值在抗oxLDL IgG（1.39±0.36对1.05±0.3，P< .05）和IgM（2.15±0.75对1.43±0.43，P< .01），以及抗MDA-LDL IgG（3.05±0.74对2.04±0.42，P< .01）和IgM（5.55±1.79对2.9±0.85，P< .01）方面显著高于CS。CRF患者的抗MDA-HSA抗体滴度也高于CS（IgG为2.49±0.5对1.46±0.39，P< .01；IgM为2.80±1.03对1.26±0.43，P< .01）。（摘要截断于250字）
